Intraocular daunorubicin for the treatment and prophylaxis of traumatic proliferative vitreoretinopathy.
Daunorubicin has been used in the treatment of advanced cases of human posttraumatic proliferative vitreoretinopathy. To reduce the failure rate of trauma surgery from proliferative vitreoretinopathy recent efforts have been directed toward the pharmacologic inhibition of cellular reproliferation. We administered intravitreal daunorubicin to 15 patients after vitrectomy and before silicone oil or gas injection. A solution containing 7.5 micrograms/ml of daunorubicin was infused over a ten-minute period. Anatomic success was obtained in 14 patients, and one patient had a renewed traction retinal detachment. Visual acuity improved in all patients postoperatively. We found no toxic effects to the optic nerve, the retina, the lens, or the cornea.
D003630:Daunorubicin / Q000008:administration & dosage* / Q000627:therapeutic use; D005128:Eye Diseases / Q000188:drug therapy / Q000517:prevention & control; D005131:Eye Injuries / Q000150:complications*; D006801:Humans; D012164:Retinal Diseases / Q000188:drug therapy* / Q000517:prevention & control; D014792:Visual Acuity; D014822:Vitreous Body
D003630:Daunorubicin